176 related articles for article (PubMed ID: 25429651)
1. Mechanisms of resistance against cancer therapeutic drugs.
Chatterjee S; Damle SG; Sharma AK
Curr Pharm Biotechnol; 2014; 15(12):1105-12. PubMed ID: 25429651
[TBL] [Abstract][Full Text] [Related]
2. Defeating drug resistance in cancer.
Gottesman MM; Ludwig J; Xia D; Szakács G
Discov Med; 2006 Feb; 6(31):18-23. PubMed ID: 17234123
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
4. Gene Silencing Strategies in Cancer Therapy: An Update for Drug Resistance.
Naghizadeh S; Mansoori B; Mohammadi A; Sakhinia E; Baradaran B
Curr Med Chem; 2019; 26(34):6282-6303. PubMed ID: 29611475
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
Sui H; Zhu L; Deng W; Li Q
Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
Cascorbi I; Haenisch S
Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
[TBL] [Abstract][Full Text] [Related]
7. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
Yu M; Ocana A; Tannock IF
Cancer Metastasis Rev; 2013 Jun; 32(1-2):211-27. PubMed ID: 23093326
[TBL] [Abstract][Full Text] [Related]
8. Targeting metabolic flexibility via angiopoietin-like 4 protein sensitizes metastatic cancer cells to chemotherapy drugs.
Lim MMK; Wee JWK; Soong JC; Chua D; Tan WR; Lizwan M; Li Y; Teo Z; Goh WWB; Zhu P; Tan NS
Mol Cancer; 2018 Oct; 17(1):152. PubMed ID: 30342537
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
10. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
11. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
[TBL] [Abstract][Full Text] [Related]
12. Classical resistance mechanisms.
Jäeger W
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):46-8. PubMed ID: 19203536
[No Abstract] [Full Text] [Related]
13. Relevance of multidrug resistance in the age of targeted therapy.
Türk D; Szakács G
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
[TBL] [Abstract][Full Text] [Related]
14. Targeting multidrug resistance in cancer.
Szakács G; Paterson JK; Ludwig JA; Booth-Genthe C; Gottesman MM
Nat Rev Drug Discov; 2006 Mar; 5(3):219-34. PubMed ID: 16518375
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
16. Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance.
Li S; Zhang W; Yin X; Xing S; Xie HQ; Cao Z; Zhao B
Anticancer Agents Med Chem; 2015; 15(4):423-32. PubMed ID: 25929575
[TBL] [Abstract][Full Text] [Related]
17. Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?
Alama A; Orengo AM; Ferrini S; Gangemi R
Drug Discov Today; 2012 May; 17(9-10):435-42. PubMed ID: 21315830
[TBL] [Abstract][Full Text] [Related]
18. Impact of breast cancer resistance protein on cancer treatment outcomes.
Ross DD; Nakanishi T
Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
[TBL] [Abstract][Full Text] [Related]
19. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
[TBL] [Abstract][Full Text] [Related]
20. Triterpenoids as reversal agents for anticancer drug resistance treatment.
Yan XJ; Gong LH; Zheng FY; Cheng KJ; Chen ZS; Shi Z
Drug Discov Today; 2014 Apr; 19(4):482-8. PubMed ID: 23954181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
